SARS-CoV-2 Mpro-IN-23

SARS-CoV-2 Mpro-IN-23

• UNSPSC Description: SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor for SARS-CoV-2 main protease (Mpro), which inhibits wildtype Mpro and mutant Mpro variants, with IC50 of 0.057-0.92 μM. SARS-CoV-2 Mpro-IN-23 inhibits the post-entry viral processes of wild-type SARS-CoV-2 single-round infectious particles (SRIPs), suppresses the viral replication of Mpro wildtype and Mpro mutants with EC50 of 0.02-0.52 μM[1].
• Target Antigen: SARS-CoV; Virus Protease
• Type: Reference compound
• Related Pathways: Anti-infection
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/sars-cov-2-mpro-in-23.html
• Smiles: C[C@@]1(CC[C@]2([C@@]([H])(C1)C([C@]3(CC2)C)=CC(C4[C@]3(CC[C@@]5([C@@]4(CC[C@@H](C5(C)C)O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)C(ONC(C(OC)=O)CCSC)=O)O)O)C(ONC(CCSC)C(OC)=O)=O)C)[H])C)=O)C)C(O)=O
• Molecular Weight: 1145.38
• References & Citations: [1]Le UNP, et al., Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants. Antiviral Res. 2024 Jul;227:105920.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported